8-KOther EventsExhibits & Filings

AbbVie Inc. 8-K Report, Temporary Suspension of Trading Under Employee Benefit Plans (May 1, 2018)

Filed May 1, 2018For Securities:ABBV

Summary

AbbVie Inc. (ABBV) filed an 8-K on May 1, 2018, primarily to announce the launch of a significant tender offer to repurchase up to $7.5 billion of its common stock. This tender offer, which spans a price range of $99 to $114 per share, is a key capital allocation strategy that could impact the company's outstanding share count and potentially return capital to shareholders. Investors should note the offer's expiration date of May 29, 2018, unless extended, and are strongly encouraged to review the detailed offer documents for specific terms and conditions. Furthermore, the filing addresses a temporary suspension of trading for certain transactions within the company's employee benefit plans, specifically the AbbVie Savings Plan and the AbbVie Puerto Rico Savings Plan. This suspension is a consequence of the tender offer and may lead to a "blackout period" under Sarbanes-Oxley Act regulations. If this blackout period is triggered, it would prohibit directors and executive officers from trading company equity securities for a defined duration, estimated to potentially begin around May 23, 2018, and extend through June 13, 2018. The company has notified its directors and officers about this potential restriction.

Key Highlights

  • 1AbbVie launched a tender offer to repurchase up to $7.5 billion of its common stock.
  • 2The tender offer price range is between $99 and $114 per share.
  • 3The offer is set to expire on May 29, 2018, unless extended by the company.
  • 4A temporary suspension of certain transactions in company stock is in place for participants in the AbbVie Savings Plan and AbbVie Puerto Rico Savings Plan.
  • 5A potential "blackout period" under Sarbanes-Oxley Act regulations could restrict trading by directors and executive officers.
  • 6The potential blackout period, if triggered, is estimated to start around May 23, 2018, and last until approximately June 13, 2018.
  • 7The company has formally notified its directors and executive officers of the potential trading restrictions.

Frequently Asked Questions

The primary purpose of this 8-K filing is to formally announce AbbVie Inc.'s launch of a tender offer to repurchase up to $7.5 billion of its common stock and to provide notice regarding a potential temporary suspension of trading for certain employee benefit plan participants and company insiders due to this tender offer, which could trigger a blackout period under Sarbanes-Oxley regulations.

A "blackout period" is a restriction imposed under Section 306(a) of the Sarbanes-Oxley Act and Regulation BTR. If triggered (meaning 50% or more of the participants in the company's savings plans elect to participate in the tender offer), it prohibits directors and executive officers of AbbVie from purchasing, selling, or otherwise acquiring or transferring any company equity securities acquired in connection with their employment or service. This restriction is temporary and aims to prevent insider trading during periods of significant corporate events affecting stock value.

Investors who wish to participate in the tender offer should carefully read the Offer to Purchase and the related Letter of Transmittal, which contain important information about the terms, conditions, and procedures. They can obtain these materials, along with other related filings, for free from the SEC's website (www.sec.gov) or by contacting AbbVie's Investor Relations. The offer is valid until May 29, 2018, unless extended.

A tender offer to repurchase stock is typically a capital allocation strategy. It can indicate that the company believes its stock is undervalued, or it may be a way to return capital to shareholders. It can also be used to offset the dilutive effects of stock-based compensation. While it's a significant financial action, this filing itself does not provide direct insight into the company's ongoing financial health or a fundamental shift in strategy beyond how it plans to manage its capital and shares outstanding.